ZURICH, February 24, 2015 /PRNewswire/ --
Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced today that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No. 8,961,947. The addition of this granted patent further strengthens Kuros' leading position in synthetic in-situ forming biomaterials.
Kuros is developing a portfolio of biomaterial, and bioactive-biomaterial combination, products. The Company's product candidates are based on two different matrix technology platforms. Kuros' most advanced candidate based on the synthetic technology to which this allowed patent application relates is KUR-023, Kuros' dural sealant. This product has successfully completed a European clinical study assessing its safety and efficacy and is being prepared for CE marking.
Kuros' other matrix technology is based on a fibrin matrix. The Company's most advanced fibrin matrix technology related product candidates, KUR-111 and KUR-113, have achieved positive results in large Phase II trials in bone repair indications.
Didier Cowling, Chief Executive Officer at Kuros, says:"This patent further builds on Kuros' proprietary position in synthetic hydrogel technology and strengthens the protection over its sealant product candidates."
Kuros is focused on the development of novel biomaterials and bioactive-biomaterial combination products in therapeutic areas covering sealants, orthobiologics and surgical wounds.
Kuros has two biomaterial technology platforms, one based on fibrin sealants and the other based on its own proprietary synthetic technology that can mimic fibrin in many of its attributes. These materials can be used alone or in combination with biologically active molecules.
Kuros' combination products are designed to mimic the body's natural healing process. The products consist of fusion proteins of naturally occurring bioactive factors, covalently incorporated into fibrin or synthetic matrices. The incorporation of the biologically active molecules into the injectable matrices aims to maximize their activity by retention at the site of action. Kuros products are designed to combine ease of application with localized delivery. Kuros has a number of methodologies to achieve the desired retention and release profiles of the biologically active molecules.
Kuros' has a diverse pipeline of product candidates with its most advanced product candidates being in sealants and orthobiologics.
Since its creation, Kuros has raised over $150 million. The company is located in Zurich, Switzerland.
Didier Cowling, CEO - +41(0)44-200-56-00
Alistair Irvine, CBO - +41(0)44-200-56-00
For International Media Enquires:
Citigate Dewe Rogerson
David Dible, Sylvie Berrebi, +44(0)207-638-9571